Change in Biomarker Profile After Neoadjuvant Chemotherapy is Prognostic and Common Among Patients with HER2+ Breast Cancer.

Conversion of pre-NAC biomarker profiles of HR+HER2– and HR+HER2+ to triple-negative breast cancer (TNBC) post-NAC may be associated with worse event-free survival, hazard ratios of 2.23 (95 % confidence interval [CI], 0.90–5.53; p = 0.08), trending toward significance, and 36.7 (95 % CI, 2.2–610.8; p = 0.01), respectively.

also in 131 other papers

As shown in Table 4 , we found that the conversion of two pre-NAC biomarker profiles, HR+HER2– ( n = 14) and HR+HER2+ ( n = 1), to TNBC was associated with worse disease-free survival, with respective hazard ratios of 2.23 (95 % CI, 0.90–5.53; p = 0.08, trending towards significance) and 36.7 (95 % CI, 2.2–610.8; p = 0.01).

also in 146 other papers